Ercc1 (ERCC excision repair 1, endonuclease non-catalytic subunit) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Gene: Ercc1 (ERCC excision repair 1, endonuclease non-catalytic subunit) Rattus norvegicus
Analyze
Symbol: Ercc1
Name: ERCC excision repair 1, endonuclease non-catalytic subunit
RGD ID: 1306992
Description: Predicted to enable DNA binding activity; TFIID-class transcription factor complex binding activity; and promoter-specific chromatin binding activity. Predicted to contribute to 3' overhang single-stranded DNA endodeoxyribonuclease activity and DNA binding activity. Involved in several processes, including response to cadmium ion; response to immobilization stress; and response to sucrose. Predicted to be located in chromosome, telomeric region and nucleoplasm. Predicted to be part of ERCC4-ERCC1 complex and nucleotide-excision repair factor 1 complex. Predicted to be active in nucleus. Used to study lung carcinoma. Biomarker of alcohol use disorder. Human ortholog(s) of this gene implicated in several diseases, including azoospermia; carcinoma (multiple); cerebrooculofacioskeletal syndrome 4; gastrointestinal system cancer (multiple); and hematologic cancer (multiple). Orthologous to human ERCC1 (ERCC excision repair 1, endonuclease non-catalytic subunit); PARTICIPATES IN nucleotide excision repair pathway; INTERACTS WITH (+)-pilocarpine; (+)-schisandrin B; 2,2',4,4'-Tetrabromodiphenyl ether.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: DNA excision repair protein ERCC-1; excision repair cross-complementation group 1; excision repair cross-complementing 1; excision repair cross-complementing rodent repair deficiency, complementation group 1; LOC292673
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr8188,099,308 - 88,135,966 (+)NCBIGRCr8
mRatBN7.2178,971,310 - 79,007,963 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl178,996,390 - 79,007,963 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx184,385,658 - 84,396,816 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0192,943,314 - 92,954,535 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0186,140,755 - 86,151,914 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0180,256,973 - 80,268,198 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl180,256,973 - 80,268,198 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0181,523,234 - 81,534,459 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4178,711,249 - 78,722,474 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1178,787,675 - 78,800,533 (+)NCBI
Celera173,458,746 - 73,469,951 (+)NCBICelera
Cytogenetic Map1q21NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acute lymphoblastic leukemia  (ISO)
acute myeloid leukemia  (ISO)
alcohol use disorder  (IEP)
anemia  (ISO)
Arsenic Poisoning  (ISO)
azoospermia  (ISO)
breast cancer  (ISO)
cerebrooculofacioskeletal syndrome 4  (ISO)
Chromosome Aberrations  (ISO)
Cockayne syndrome  (ISO)
colorectal cancer  (ISO)
Colorectal Neoplasms  (ISO)
degenerative disc disease  (ISO)
disease of cellular proliferation  (ISO)
Drug-induced Neutropenia  (ISO)
Drug-Related Side Effects and Adverse Reactions  (ISO)
esophagus adenocarcinoma  (ISO)
esophagus squamous cell carcinoma  (ISO)
Experimental Diabetes Mellitus  (IEP)
Failure to Thrive  (ISO)
Gastrointestinal Neoplasms  (ISO)
genetic disease  (ISO)
Genetic Predisposition to Disease  (ISO)
Germ Cell and Embryonal Neoplasms  (ISO)
hepatocellular carcinoma  (ISO)
high grade glioma  (ISO)
Inflammation  (ISO)
kidney failure  (ISO)
Laryngeal Neoplasms  (ISO)
lipodystrophy  (ISO)
lung adenocarcinoma  (ISO)
lung carcinoma  (IDA)
Lung Neoplasms  (ISO)
lung non-small cell carcinoma  (ISO)
melanoma  (ISO)
multiple myeloma  (ISO)
myelofibrosis  (ISO)
Myeloid Leukemia, Chronic-Phase  (ISO)
Neoplasm Metastasis  (ISO)
osteoarthritis  (ISO)
osteoporosis  (ISO)
osteosarcoma  (ISO)
ovarian cancer  (ISO)
ovary epithelial cancer  (ISO)
pancreatic cancer  (ISO)
peripheral nervous system disease  (ISO)
Premature Aging  (ISO)
Prostatic Neoplasms  (ISO)
Reperfusion Injury  (IMP)
stomach cancer  (ISO)
Stomach Neoplasms  (ISO)
Testicular Neoplasms  (ISO)
transient cerebral ischemia  (ISO)
Uterine Cervical Neoplasms  (ISO)
xeroderma pigmentosum group D  (ISO)
XFE progeroid syndrome  (ISS)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-pilocarpine  (EXP)
(+)-schisandrin B  (EXP)
(-)-epigallocatechin 3-gallate  (ISO)
(-)-quinic acid  (ISO)
1,2-dimethylhydrazine  (ISO)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (ISO)
1H-pyrazole  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (EXP,ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4-dinitrotoluene  (EXP)
2-hydroxypropanoic acid  (ISO)
3,3',5,5'-tetrabromobisphenol A  (ISO)
3-aminobenzamide  (EXP,ISO)
4-amino-2,6-dinitrotoluene  (EXP)
4-hydroxynon-2-enal  (ISO)
4-hydroxyphenyl retinamide  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-fluorouracil  (ISO)
5-formyltetrahydrofolic acid  (ISO)
7,12-dimethyltetraphene  (ISO)
acrolein  (ISO)
aflatoxin B1  (ISO)
aldehydo-D-glucose  (ISO)
alpha-pinene  (ISO)
amphibole asbestos  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
azathioprine  (ISO)
benzene  (ISO)
benzo[a]pyrene  (ISO)
benzo[a]pyrene diol epoxide I  (ISO)
bisphenol A  (EXP)
cadmium dichloride  (ISO)
camptothecin  (ISO)
carbon nanotube  (ISO)
chlorpyrifos  (ISO)
choline  (ISO)
cisplatin  (EXP,ISO)
cobalt atom  (ISO)
cobalt dichloride  (EXP,ISO)
copper(II) sulfate  (ISO)
curcumin  (EXP,ISO)
cyclophosphamide  (EXP)
cyclosporin A  (ISO)
cyproconazole  (EXP)
D-glucose  (ISO)
dioxygen  (EXP)
disodium selenite  (ISO)
dorsomorphin  (ISO)
doxorubicin  (ISO)
elemental selenium  (ISO)
endosulfan  (EXP)
epoxiconazole  (EXP)
ethanol  (EXP)
finasteride  (EXP)
flutamide  (EXP)
folic acid  (ISO)
fonofos  (ISO)
furan  (EXP)
gefitinib  (ISO)
gentamycin  (EXP)
glucose  (ISO)
hexadecanoic acid  (ISO)
hydrogen peroxide  (ISO)
irinotecan  (ISO)
isotretinoin  (ISO)
L-methionine  (ISO)
lead diacetate  (EXP)
lead nitrate  (ISO)
lipopolysaccharide  (ISO)
lithium chloride  (ISO)
lovastatin  (EXP)
MeIQx  (ISO)
melatonin  (ISO)
methylseleninic acid  (ISO)
microcystin RR  (ISO)
myristicin  (ISO)
N-acetyl-L-cysteine  (ISO)
oxaliplatin  (ISO)
ozone  (ISO)
paracetamol  (EXP,ISO)
paraquat  (ISO)
PD 0325901  (ISO)
pemetrexed  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
PhIP  (ISO)
pinosylvin  (ISO)
pirinixic acid  (ISO)
platinum  (ISO)
platinum(0)  (ISO)
prochloraz  (EXP)
pyrazinecarboxamide  (EXP)
quercetin  (ISO)
quercitrin  (ISO)
rac-lactic acid  (ISO)
resveratrol  (EXP,ISO)
SB 203580  (ISO)
SB 431542  (ISO)
sclareol  (ISO)
selenium atom  (ISO)
sodium arsenate  (ISO)
sodium arsenite  (ISO)
sodium dichromate  (ISO)
sterigmatocystin  (EXP)
streptozocin  (EXP)
sunitinib  (ISO)
Tanshinone I  (ISO)
tetrachloromethane  (EXP,ISO)
tetraphene  (ISO)
theaflavin  (ISO)
thioacetamide  (EXP)
trans-pinosylvin  (ISO)
trichostatin A  (ISO)
triclosan  (ISO)
trovafloxacin  (ISO)
usnic acid  (ISO)
valproic acid  (ISO)
vancomycin  (ISO)
veliparib  (ISO)
vinclozolin  (EXP)
vitamin E  (ISO)
Y-27632  (ISO)
zinc atom  (ISO)
zinc sulfate  (ISO)
zinc(0)  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Pathway Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. DNA repair gene XPD and XRCC1 polymorphisms and the risk of childhood acute lymphoblastic leukemia. Batar B, etal., Leuk Res. 2009 Jun;33(6):759-63. doi: 10.1016/j.leukres.2008.11.005. Epub 2008 Dec 19.
2. SNPs and taxane toxicity in breast cancer patients. Boso V, etal., Pharmacogenomics. 2014;15(15):1845-58. doi: 10.2217/pgs.14.127.
3. Polymorphisms of cancer-related genes and risk of multipleprimary malignancies involving colorectal cancer Cao P, etal., Turk J Med Sci. 2017 Nov 13;47(5):1549-1554. doi: 10.3906/sag-1612-119.
4. DNA damage drives accelerated bone aging via an NF-kappaB-dependent mechanism. Chen Q, etal., J Bone Miner Res. 2013 May;28(5):1214-28. doi: 10.1002/jbmr.1851.
5. Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. Cibeira MT, etal., Leuk Res. 2011 Sep;35(9):1178-83. doi: 10.1016/j.leukres.2011.02.009. Epub 2011 Mar 23.
6. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cortejoso L, etal., Cancer Chemother Pharmacol. 2013 Jun;71(6):1463-72. doi: 10.1007/s00280-013-2145-6. Epub 2013 Mar 31.
7. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. Deenen MJ, etal., Cancer Chemother Pharmacol. 2015 Dec;76(6):1285-95. doi: 10.1007/s00280-015-2872-y. Epub 2015 Oct 23.
8. DNA adduct formation and oxidative stress in colon and liver of Big Blue rats after dietary exposure to diesel particles. Dybdahl M, etal., Carcinogenesis. 2003 Nov;24(11):1759-66. Epub 2003 Aug 14.
9. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Fareed KR, etal., Br J Cancer. 2010 May 25;102(11):1600-7. doi: 10.1038/sj.bjc.6605686. Epub 2010 May 11.
10. Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma. Fautrel A, etal., J Hepatol. 2005 Aug;43(2):288-93. doi: 10.1016/j.jhep.2005.02.020. Epub 2005 Apr 25.
11. Dynamic regulation of cerebral DNA repair genes by psychological stress. Forsberg K, etal., Mutat Res Genet Toxicol Environ Mutagen. 2015 Jan 15;778:37-43. doi: 10.1016/j.mrgentox.2014.12.003. Epub 2014 Dec 27.
12. Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations. Ganzinelli M, etal., Eur J Cancer. 2011 May;47(7):1086-94. doi: 10.1016/j.ejca.2010.11.029. Epub 2011 Jan 7.
13. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
14. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
15. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients. Hao T, etal., Asian Pac J Cancer Prev. 2012;13(8):3821-4.
16. Myelofibrosis in Philadelphia chromosome-negative myeloproliferative neoplasms is associated with aberrant karyotypes. Hauck G, etal., Cancer Genet. 2013 Apr;206(4):116-23. doi: 10.1016/j.cancergen.2013.02.002. Epub 2013 Apr 6.
17. Excision repair cross-complementing 1 expression protects against ischemic injury following middle cerebral artery occlusion in the rat brain. He KY, etal., Gene Ther. 2009 Jul;16(7):840-8. Epub 2009 May 14.
18. Evaluation of cell proliferation, apoptosis, and DNA-repair genes as potential biomarkers for ethanol-induced CNS alterations. Hicks SD, etal., BMC Neurosci. 2012 Oct 25;13:128. doi: 10.1186/1471-2202-13-128.
19. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Hirakawa M, etal., Cancer Chemother Pharmacol. 2013 Mar;71(3):789-97. doi: 10.1007/s00280-013-2073-5. Epub 2013 Jan 22.
20. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Huang J, etal., Med Oncol. 2013 Mar;30(1):343. doi: 10.1007/s12032-012-0343-4. Epub 2012 Dec 21.
21. ERCC1 and ERCC2 polymorphisms and risk of idiopathic azoospermia in a Chinese population. Ji G, etal., Reprod Biomed Online. 2008 Jul;17(1):36-41.
22. Defective transcription initiation causes postnatal growth failure in a mouse model of nucleotide excision repair (NER) progeria. Kamileri I, etal., Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2995-3000. doi: 10.1073/pnas.1114941109. Epub 2012 Feb 8.
23. DNA damage triggers a chronic autoinflammatory response, leading to fat depletion in NER progeria. Karakasilioti I, etal., Cell Metab. 2013 Sep 3;18(3):403-15. doi: 10.1016/j.cmet.2013.08.011.
24. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Khrunin AV, etal., Pharmacogenomics J. 2010 Feb;10(1):54-61. Epub 2009 Sep 29.
25. Association of GSTT1 polymorphism with acute myeloid leukemia risk is dependent on smoking status. Kim HN, etal., Leuk Lymphoma. 2012 Apr;53(4):681-7. doi: 10.3109/10428194.2011.625576. Epub 2012 Jan 3.
26. Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia. Kong JH, etal., Int J Hematol. 2012 Sep;96(3):327-33. doi: 10.1007/s12185-012-1142-6. Epub 2012 Jul 21.
27. High expression of ERCC1, FLT1, NME4 and PCNA associated with poor prognosis and advanced stages in myelodysplastic syndrome. Kracmarova A, etal., Leuk Lymphoma. 2008 Jul;49(7):1297-305. doi: 10.1080/10428190802129918.
28. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. Krivak TC, etal., J Clin Oncol. 2008 Jul 20;26(21):3598-606. doi: 10.1200/JCO.2008.16.1323.
29. Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Kuptsova N, etal., Blood. 2007 May 1;109(9):3936-44. Epub 2006 Dec 29.
30. Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. Lambrechts S, etal., BMC Pharmacol Toxicol. 2015 Feb 27;16:2. doi: 10.1186/s40360-015-0001-5.
31. Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Lee KM, etal., Clin Cancer Res. 2005 Jun 15;11(12):4620-6.
32. Expression profiles of DNA repair-related genes in rat target organs under subchronic cadmium exposure. Lei YX, etal., Genet Mol Res. 2015 Jan 26;14(1):515-24. doi: 10.4238/2015.January.26.5.
33. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population. Li J, etal., Tumour Biol. 2014 Aug;35(8):7569-74. doi: 10.1007/s13277-014-1959-0. Epub 2014 May 4.
34. Effects of sucrose and cornstarch on 2-amino-3-methylimidazo[4,5-f]quinoline (IQ)-induced colon and liver carcinogenesis in F344 rats. Lindecrona RH, etal., Cancer Lett. 2004 Jun 8;209(1):17-24.
35. Polymorphisms of multiple genes involved in NER pathway predict prognosis of gastric cancer. Liu J, etal., Oncotarget. 2016 Jul 26;7(30):48130-48142. doi: 10.18632/oncotarget.10173.
36. Molecular analysis of DNA repair gene methylation and protein expression during chemical-induced rat lung carcinogenesis. Liu WB, etal., Biochem Biophys Res Commun. 2011 May 20;408(4):595-601. doi: 10.1016/j.bbrc.2011.04.067. Epub 2011 Apr 21.
37. Laryngeal cancer risk and common single nucleotide polymorphisms in nucleotide excision repair pathway genes ERCC1, ERCC2, ERCC3, ERCC4, ERCC5 and XPA. Lu B, etal., Gene. 2014 May 25;542(1):64-8. doi: 10.1016/j.gene.2014.02.043. Epub 2014 Feb 26.
38. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy. Lu ZM, etal., Tumour Biol. 2014 Apr;35(4):2941-8. doi: 10.1007/s13277-013-1378-7. Epub 2013 Dec 8.
39. Prognostic Value of Excision Repair Cross-Complementing mRNA Expression in Gastric Cancer. Luo SS, etal., Biomed Res Int. 2018 Oct 17;2018:6204684. doi: 10.1155/2018/6204684. eCollection 2018.
40. Deficiency of DNA repair nuclease ERCC1-XPF promotes prostate cancer progression in a tissue recombination model. Matoka DJ, etal., Prostate. 2012 Aug 1;72(11):1214-22. doi: 10.1002/pros.22472. Epub 2011 Dec 27.
41. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Middleton MR, etal., Ann Oncol. 2015 Oct;26(10):2173-9. doi: 10.1093/annonc/mdv308. Epub 2015 Jul 22.
42. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Monzo M, etal., Blood. 2006 Jun 15;107(12):4871-9. Epub 2006 Feb 28.
43. Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population. Ni M, etal., Sci Rep. 2014 Feb 17;4:4112. doi: 10.1038/srep04112.
44. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. Olaussen KA, etal., N Engl J Med. 2006 Sep 7;355(10):983-91.
45. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
46. Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukemia. Pakakasama S, etal., Pediatr Blood Cancer. 2007 Jan;48(1):16-20.
47. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
48. ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy. Qin X, etal., Tumour Biol. 2014 May;35(5):4697-704. doi: 10.1007/s13277-014-1615-8. Epub 2014 Jan 18.
49. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
50. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
51. Comprehensive gene review and curation RGD comprehensive gene curation
52. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Ryu JS, etal., Lung Cancer. 2004 Jun;44(3):311-6.
53. The multi-replication protein A (RPA) system--a new perspective. Sakaguchi K, etal., FEBS J. 2009 Feb;276(4):943-63. doi: 10.1111/j.1742-4658.2008.06841.x. Epub 2009 Jan 12.
54. Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer. Song X, etal., Sci Rep. 2017 Sep 18;7(1):11785. doi: 10.1038/s41598-017-08257-7.
55. The genotype distribution of the XRCC1, XRCC3, and XPD DNA repair genes and their role for the development of acute myeloblastic leukemia. Sorour A, etal., Genet Test Mol Biomarkers. 2013 Mar;17(3):195-201. doi: 10.1089/gtmb.2012.0278. Epub 2013 Feb 11.
56. Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients. Strom SS, etal., Leuk Lymphoma. 2010 Apr;51(4):598-605. doi: 10.3109/10428190903582804.
57. Involvement of ERCC1 in the pathogenesis of osteoarthritis through the modulation of apoptosis and cellular senescence. Takayama K, etal., J Orthop Res. 2014 Oct;32(10):1326-32. doi: 10.1002/jor.22656. Epub 2014 Jun 25.
58. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Tiseo M, etal., Br J Cancer. 2013 Apr 30;108(8):1695-703. doi: 10.1038/bjc.2013.127. Epub 2013 Apr 2.
59. Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Tse D, etal., Cancer Causes Control. 2008 Dec;19(10):1077-83. doi: 10.1007/s10552-008-9171-4. Epub 2008 May 14.
60. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Viguier J, etal., Clin Cancer Res. 2005 Sep 1;11(17):6212-7.
61. Nucleotide excision repair gene expression in the rat conceptus during organogenesis. Vinson RK and Hales BF, Mutat Res. 2001 Jul 12;486(2):113-23.
62. Accelerated aging of intervertebral discs in a mouse model of progeria. Vo N, etal., J Orthop Res. 2010 Dec;28(12):1600-7. doi: 10.1002/jor.21153.
63. Effect of increased intake of dietary animal fat and fat energy on oxidative damage, mutation frequency, DNA adduct level and DNA repair in rat colon and liver. Vogel U, etal., Free Radic Res. 2003 Sep;37(9):947-56.
64. Genotoxic stress and activation of novel DNA repair enzymes in human endothelial cells and in the retinas and kidneys of streptozotocin diabetic rats. Wang C, etal., Diabetes Metab Res Rev. 2012 May;28(4):329-37. doi: 10.1002/dmrr.2279.
65. Polymorphisms in ERCC1 and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Wang SL, etal., Leuk Res. 2006 Nov;30(11):1341-5. Epub 2006 May 24.
66. Role of single nucleotide polymorphisms of DNA repair genes in susceptibility to pancreatic cancer in Chinese population. Ying MF and Zhao R, Genet Mol Res. 2016 Mar 18;15(1). doi: 10.4238/gmr.15017273.
67. DNA repair pathway profiling and microsatellite instability in colorectal cancer. Yu J, etal., Clin Cancer Res. 2006 Sep 1;12(17):5104-11. doi: 10.1158/1078-0432.CCR-06-0547.
68. The polymorphisms of miRNA-binding site in MLH3 and ERCC1 were linked to the risk of colorectal cancer in a case-control study. Zhang Q, etal., Cancer Med. 2018 Apr;7(4):1264-1274. doi: 10.1002/cam4.1319. Epub 2018 Mar 8.
69. Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer. Zheng DL, etal., Genet Mol Res. 2016 Apr 26;15(2). doi: 10.4238/gmr.15027384.
70. Systematic review on the association between ERCC1 rs3212986 and ERCC2 rs13181 polymorphisms and glioma risk. Zhou CX and Zhao JH, Genet Mol Res. 2015 Mar 31;14(1):2868-75. doi: 10.4238/2015.March.31.17.
Additional References at PubMed
PMID:3290851   PMID:7559382   PMID:7657672   PMID:8197175   PMID:8275084   PMID:8811092   PMID:9197240   PMID:9256505   PMID:9722633   PMID:10413517   PMID:10454634   PMID:10834928  
PMID:11707424   PMID:12466203   PMID:14690602   PMID:14734547   PMID:15199134   PMID:15280420   PMID:15692571   PMID:15979950   PMID:16076955   PMID:16682947   PMID:17055345   PMID:17173483  
PMID:17183314   PMID:17614221   PMID:17720715   PMID:17912366   PMID:22579284   PMID:23637614   PMID:25538220  


Genomics

Comparative Map Data
Ercc1
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr8188,099,308 - 88,135,966 (+)NCBIGRCr8
mRatBN7.2178,971,310 - 79,007,963 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl178,996,390 - 79,007,963 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx184,385,658 - 84,396,816 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0192,943,314 - 92,954,535 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0186,140,755 - 86,151,914 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0180,256,973 - 80,268,198 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl180,256,973 - 80,268,198 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0181,523,234 - 81,534,459 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4178,711,249 - 78,722,474 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1178,787,675 - 78,800,533 (+)NCBI
Celera173,458,746 - 73,469,951 (+)NCBICelera
Cytogenetic Map1q21NCBI
ERCC1
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh381945,407,334 - 45,451,547 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1945,407,334 - 45,478,828 (-)EnsemblGRCh38hg38GRCh38
GRCh371945,910,592 - 45,954,805 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 361950,604,712 - 50,619,017 (-)NCBINCBI36Build 36hg18NCBI36
Build 341950,608,532 - 50,618,642NCBI
Celera1942,716,697 - 42,733,283 (-)NCBICelera
Cytogenetic Map19q13.32NCBI
HuRef1942,340,919 - 42,357,653 (-)NCBIHuRef
CHM1_11945,913,883 - 45,930,469 (-)NCBICHM1_1
T2T-CHM13v2.01948,234,581 - 48,278,793 (-)NCBIT2T-CHM13v2.0
Ercc1
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm39719,079,016 - 19,090,449 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl719,078,703 - 19,090,449 (+)EnsemblGRCm39 Ensembl
GRCm38719,344,067 - 19,356,524 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl719,344,778 - 19,356,524 (+)EnsemblGRCm38mm10GRCm38
MGSCv37719,930,420 - 19,941,873 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36718,503,628 - 18,515,044 (+)NCBIMGSCv36mm8
Celera716,751,825 - 16,763,278 (+)NCBICelera
Cytogenetic Map7A3NCBI
cM Map79.6NCBI
Ercc1
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_0049555552,393,278 - 2,406,582 (-)EnsemblChiLan1.0
ChiLan1.0NW_0049555552,393,510 - 2,430,180 (-)NCBIChiLan1.0ChiLan1.0
ERCC1
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v22051,568,054 - 51,639,947 (-)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan11953,439,598 - 53,511,447 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01942,356,039 - 42,427,754 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11950,951,674 - 50,994,600 (-)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl1950,951,674 - 50,968,430 (-)Ensemblpanpan1.1panPan2
ERCC1
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.11110,130,353 - 110,146,660 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1110,130,481 - 110,146,602 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1109,614,480 - 109,631,191 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01110,662,831 - 110,679,536 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1110,662,958 - 110,679,533 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11110,338,665 - 110,355,163 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01109,972,731 - 109,989,322 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01110,842,133 - 110,858,633 (+)NCBIUU_Cfam_GSD_1.0
Ercc1
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_02440934917,507,594 - 17,520,240 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049367061,852,359 - 1,867,745 (-)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_0049367061,854,938 - 1,867,521 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
ERCC1
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl651,783,478 - 51,798,984 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.1651,783,537 - 51,808,898 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
ERCC1
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.1638,857,067 - 38,900,177 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl638,854,803 - 38,872,967 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366607318,458,810 - 18,478,494 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Ercc1
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046249072,288,423 - 2,298,373 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046249072,288,380 - 2,298,909 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Ercc1
80 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:61
Count of miRNA genes:57
Interacting mature miRNAs:60
Transcripts:ENSRNOT00000024113
Prediction methods:Microtar, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1554320Bmd1Bone mineral density QTL 112.20.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)150910886060548Rat
631688Hcas2Hepatocarcinoma susceptibility QTL 230.0001liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)15925874115540829Rat
2313062Bmd73Bone mineral density QTL 733.90.0001tibia mineral mass (VT:1000283)compact volumetric bone mineral density (CMO:0001730)11148131282174945Rat
2313065Bss67Bone structure and strength QTL 673.10.0001tibia area (VT:1000281)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
2313069Bss68Bone structure and strength QTL 682.90.0001tibia size trait (VT:0100001)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
2313075Bss66Bone structure and strength QTL 663.40.0001tibia length (VT:0004357)tibia length (CMO:0000450)11148131282174945Rat
2313077Bss69Bone structure and strength QTL 693.50.0001tibia strength trait (VT:1000284)bone polar moment of inertia (CMO:0001558)11148131282174945Rat
2313092Bmd72Bone mineral density QTL 722.50.0001tibia mineral mass (VT:1000283)total volumetric bone mineral density (CMO:0001728)11148131282174945Rat
2313097Bss70Bone structure and strength QTL 703.50.0001tibia strength trait (VT:1000284)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
631495Bp96Blood pressure QTL 964.52arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)122340647102268831Rat
1358359Sradr1Stress Responsive Adrenal Weight QTL 14.74adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)130882023123479925Rat
70225Bp58Blood pressure QTL 583.3arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)132356093162846471Rat
1300172Bp172Blood pressure QTL 1723.56arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)13273727390665040Rat
10059597Bp377Blood pressure QTL 3773.420.025arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)132737458199368955Rat
8552900Pigfal1Plasma insulin-like growth factor 1 level QTL 17.4blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)13483685879836858Rat
8552948Pigfal11Plasma insulin-like growth factor 1 level QTL 114.7blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)13483685879836858Rat
9589820Insglur3Insulin/glucose ratio QTL 310.750.001blood insulin amount (VT:0001560)calculated plasma insulin level (CMO:0002170)13483685879836858Rat
2313051Bss57Bone structure and strength QTL 573.70.0001tibia strength trait (VT:1000284)bone polar moment of inertia (CMO:0001558)143284731118944897Rat
2313059Bss55Bone structure and strength QTL 553.20.0001tibia size trait (VT:0100001)tibia midshaft cross-sectional area (CMO:0001717)143284731118944897Rat
2313072Bss53Bone structure and strength QTL 534.30.0001tibia length (VT:0004357)tibia length (CMO:0000450)143284731118944897Rat
2313078Bss54Bone structure and strength QTL 543.50.0001tibia area (VT:1000281)tibia midshaft cross-sectional area (CMO:0001717)143284731118944897Rat
2313094Bss58Bone structure and strength QTL 583.70.0001tibia strength trait (VT:1000284)tibia total energy absorbed before break (CMO:0001736)143284731118944897Rat
2313098Bmd70Bone mineral density QTL 703.60.0001tibia mineral mass (VT:1000283)compact volumetric bone mineral density (CMO:0001730)143284731118944897Rat
2313099Bss56Bone structure and strength QTL 562.40.0001tibia size trait (VT:0100001)tibia midshaft endosteal cross-sectional area (CMO:0001716)143284731118944897Rat
2302059Pia36Pristane induced arthritis QTL 363.80.001blood immunoglobulin amount (VT:0002460)serum immunoglobulin G1 level (CMO:0002115)14333300288333002Rat
2313402Anxrr24Anxiety related response QTL 24aggression-related behavior trait (VT:0015014)tameness/aggressiveness composite score (CMO:0002136)148963584144267916Rat
4889962Bss94Bone structure and strength QTL 943.8tibia area (VT:1000281)tibia-fibula cortical bone endosteal cross-sectional area (CMO:0001722)14936146582174945Rat
1578649Bmd8Bone mineral density QTL 84.9femur mineral mass (VT:0010011)trabecular volumetric bone mineral density (CMO:0001729)14939317294393172Rat
1578654Bss10Bone structure and strength QTL 104femur morphology trait (VT:0000559)femoral neck cortical cross-sectional area (CMO:0001702)149393172159356837Rat
634314Niddm44Non-insulin dependent diabetes mellitus QTL 44blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)149393289199050459Rat
6903308Scl36Serum cholesterol QTL 3620.0125blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)15386304190532583Rat
4889919Bss86Bone structure and strength QTL 864.1tibia area (VT:1000281)tibia midshaft total cross-sectional area (CMO:0001715)15389511782174945Rat
4889929Bss87Bone structure and strength QTL 876.7tibia area (VT:1000281)tibia-fibula cortical bone endosteal cross-sectional area (CMO:0001722)15389511782174945Rat
61342Bp27Blood pressure QTL 273.40.0006arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)15673266898773277Rat
2300164Bmd44Bone mineral density QTL 445.40.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)156949932101949932Rat
2298545Neuinf8Neuroinflammation QTL 84.6nervous system integrity trait (VT:0010566)spinal cord beta-2 microglobulin mRNA level (CMO:0002125)157336763151090257Rat
1300121Hrtrt1Heart rate QTL 13.7heart pumping trait (VT:2000009)heart rate (CMO:0000002)165789093115540829Rat
7421628Bp361Blood pressure QTL 3610.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)166023617118608521Rat
631512Scl6Serum cholesterol level QTL 69.6blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)17219768090508767Rat
1358192Ept13Estrogen-induced pituitary tumorigenesis QTL 133.4pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)177494165122494165Rat
10054135Gmadr2Adrenal mass QTL 21.970.0129adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)177857876122857876Rat
1549903Bp267Blood pressure QTL 267arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)177876254106047988Rat
61344Bp29Blood pressure QTL 297.5arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)178350581123350581Rat
7411712Strs4Sensitivity to stroke QTL 48.7cerebrum integrity trait (VT:0010549)percentage of study population developing cerebrovascular lesions during a period of time (CMO:0000932)178430536123430536Rat
61433Cia2Collagen induced arthritis QTL 25joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)17843075491209302Rat
1582234Gluco18Glucose level QTL 183.40.0003blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)178479925123479925Rat

Markers in Region
BE120839  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2179,008,387 - 79,008,538 (+)MAPPERmRatBN7.2
Rnor_6.0180,268,623 - 80,268,773NCBIRnor6.0
Rnor_5.0181,534,884 - 81,535,034UniSTSRnor5.0
RGSC_v3.4178,722,899 - 78,723,049UniSTSRGSC3.4
Celera173,470,376 - 73,470,526UniSTS
RH 3.4 Map1794.6UniSTS
Cytogenetic Map1q21UniSTS
ERCC1  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2179,001,770 - 79,001,871 (+)MAPPERmRatBN7.2
Rnor_6.0180,262,008 - 80,262,108NCBIRnor6.0
Rnor_5.0181,528,269 - 81,528,369UniSTSRnor5.0
RGSC_v3.4178,716,284 - 78,716,384UniSTSRGSC3.4
Celera173,463,775 - 73,463,875UniSTS
Cytogenetic Map1q21UniSTS


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 3 35 26 17 12 17 2 5 74 31 40 11 2
Low 8 31 24 7 24 6 6 4 1 6
Below cutoff

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000024113   ⟹   ENSRNOP00000024113
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl178,996,531 - 79,007,960 (+)Ensembl
Rnor_6.0 Ensembl180,256,973 - 80,268,198 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000104471   ⟹   ENSRNOP00000087227
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl178,996,390 - 79,006,013 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000117664   ⟹   ENSRNOP00000090301
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl178,998,625 - 79,007,963 (+)Ensembl
RefSeq Acc Id: NM_001106228   ⟹   NP_001099698
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8188,124,741 - 88,135,966 (+)NCBI
mRatBN7.2178,996,736 - 79,007,963 (+)NCBI
Rnor_6.0180,256,973 - 80,268,198 (+)NCBI
Rnor_5.0181,523,234 - 81,534,459 (+)NCBI
RGSC_v3.4178,711,249 - 78,722,474 (+)RGD
Celera173,458,746 - 73,469,951 (+)RGD
Sequence:
RefSeq Acc Id: XM_006228395   ⟹   XP_006228457
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8188,124,921 - 88,135,964 (+)NCBI
mRatBN7.2178,996,912 - 79,007,962 (+)NCBI
Rnor_6.0180,257,156 - 80,268,197 (+)NCBI
Rnor_5.0181,523,234 - 81,534,459 (+)NCBI
Sequence:
RefSeq Acc Id: XM_006228396   ⟹   XP_006228458
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8188,125,009 - 88,135,964 (+)NCBI
mRatBN7.2178,997,007 - 79,007,962 (+)NCBI
Rnor_6.0180,257,287 - 80,268,197 (+)NCBI
Rnor_5.0181,523,234 - 81,534,459 (+)NCBI
Sequence:
RefSeq Acc Id: XM_039103935   ⟹   XP_038959863
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8188,124,143 - 88,135,964 (+)NCBI
mRatBN7.2178,996,095 - 79,007,962 (+)NCBI
RefSeq Acc Id: XM_039103939   ⟹   XP_038959867
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8188,099,308 - 88,135,964 (+)NCBI
mRatBN7.2178,971,310 - 79,007,962 (+)NCBI
Reference Protein Sequences
RefSeq Acc Id: NP_001099698   ⟸   NM_001106228
- UniProtKB: D3ZAQ9 (UniProtKB/TrEMBL),   A6J8M3 (UniProtKB/TrEMBL),   A0A8I6GI31 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_006228457   ⟸   XM_006228395
- Peptide Label: isoform X1
- UniProtKB: D3ZAQ9 (UniProtKB/TrEMBL),   A6J8M3 (UniProtKB/TrEMBL),   A0A8I6GI31 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_006228458   ⟸   XM_006228396
- Peptide Label: isoform X1
- UniProtKB: D3ZAQ9 (UniProtKB/TrEMBL),   A6J8M3 (UniProtKB/TrEMBL),   A0A8I6GI31 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000024113   ⟸   ENSRNOT00000024113
RefSeq Acc Id: XP_038959867   ⟸   XM_039103939
- Peptide Label: isoform X1
- UniProtKB: D3ZAQ9 (UniProtKB/TrEMBL),   A6J8M3 (UniProtKB/TrEMBL),   A0A8I6GI31 (UniProtKB/TrEMBL)
RefSeq Acc Id: XP_038959863   ⟸   XM_039103935
- Peptide Label: isoform X1
- UniProtKB: D3ZAQ9 (UniProtKB/TrEMBL),   A6J8M3 (UniProtKB/TrEMBL),   A0A8I6GI31 (UniProtKB/TrEMBL)
RefSeq Acc Id: ENSRNOP00000087227   ⟸   ENSRNOT00000104471
RefSeq Acc Id: ENSRNOP00000090301   ⟸   ENSRNOT00000117664
Protein Domains
ERCC1-like central

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-D3ZAQ9-F1-model_v2 AlphaFold D3ZAQ9 1-298 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13689768
Promoter ID:EPDNEW_R292
Type:initiation region
Name:Ercc1_1
Description:ERCC excision repair 1, endonuclease non-catalytic subunit
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0180,256,990 - 80,257,050EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:1306992 AgrOrtholog
BioCyc Gene G2FUF-60511 BioCyc
Ensembl Genes ENSRNOG00000017839 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000024113 ENTREZGENE
  ENSRNOT00000024113.6 UniProtKB/TrEMBL
  ENSRNOT00000104471.1 UniProtKB/TrEMBL
  ENSRNOT00000117664.1 UniProtKB/TrEMBL
Gene3D-CATH 3.40.50.10130 UniProtKB/TrEMBL
  5' to 3' exonuclease, C-terminal subdomain UniProtKB/TrEMBL
InterPro DNA_repair_Rad10 UniProtKB/TrEMBL
  ERCC1-like_central_dom UniProtKB/TrEMBL
  Restrct_endonuc_II-like UniProtKB/TrEMBL
  RuvA_2-like UniProtKB/TrEMBL
KEGG Report rno:292673 UniProtKB/TrEMBL
NCBI Gene 292673 ENTREZGENE
PANTHER DNA EXCISION REPAIR PROTEIN ERCC-1 UniProtKB/TrEMBL
  PTHR12749 UniProtKB/TrEMBL
Pfam HHH_5 UniProtKB/TrEMBL
  Rad10 UniProtKB/TrEMBL
PharmGKB ERCC1 RGD
PhenoGen Ercc1 PhenoGen
RatGTEx ENSRNOG00000017839 RatGTEx
Superfamily-SCOP Restrict_endonuc_II-like_core UniProtKB/TrEMBL
  RuvA_2_like UniProtKB/TrEMBL
UniProt A0A8I6A2U2_RAT UniProtKB/TrEMBL
  A0A8I6GI31 ENTREZGENE, UniProtKB/TrEMBL
  A6J8M3 ENTREZGENE, UniProtKB/TrEMBL
  D3ZAQ9 ENTREZGENE, UniProtKB/TrEMBL


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2016-06-01 Ercc1  ERCC excision repair 1, endonuclease non-catalytic subunit  Ercc1  excision repair cross-complementation group 1  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2015-02-02 Ercc1  excision repair cross-complementation group 1  Ercc1  excision repair cross-complementing rodent repair deficiency, complementation group 1  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-04-30 Ercc1  excision repair cross-complementing rodent repair deficiency, complementation group 1   Ercc1_predicted  excision repair cross-complementing rodent repair deficiency, complementation group 1 (predicted)  'predicted' is removed 2292626 APPROVED
2005-01-12 Ercc1_predicted  excision repair cross-complementing rodent repair deficiency, complementation group 1 (predicted)      Symbol and Name status set to approved 70820 APPROVED